This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Ruggeri A, Galimard JE, Paina O, Fagioli F, Tbakhi A, Yesilipek A, et al. Outcomes of unmanipulated haploidentical transplantation using post-transplant cyclophosphamide (PT-Cy) in pediatric patients with acute lymphoblastic leukemia. Transpl Cell Ther. 2021;27:424.e1–424.e9.
Fierro-Pineda JC, Tsai HL, Blackford A, Cluster A, Caywood E, Dalal J, et al. Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias. Blood Adv. 2023;7:5639–48.
Ruggeri A, Santoro N, Galimard JE, Kalwak K, Algeri M, Zubarovskaya L, et al. Matched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study. Haematologica. 2024;109:2122–30.
Kawahara Y, Morimoto A, Inagaki J, Koh K, Noguchi M, Goto H, et al. Unrelated cord blood transplantation with myeloablative conditioning for pediatric acute lymphoblastic leukemia in remission: prognostic factors. Bone Marrow Transplant. 2021;56:357–67.
Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2021;39:295–307.
Dalle JH, Balduzzi A, Bader P, Pieczonka A, Yaniv I, Lankester A, et al. The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG. Bone Marrow Transplant. 2021;56:257–66.
Merli P, Algeri M, Galaverna F, Bertaina V, Lucarelli B, Boccieri E, et al. TCRαβ/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis. Blood. 2024;143:279–89.
Hyakuna N, Hashii Y, Ishida H, Umeda K, Takahashi Y, Nagasawa M, et al. Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial. Pediatr Blood Cancer. 2019;66:e27875.
Chen TT, David AP, Barthelmess EK, MacBrayne CE. Letermovir for cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2023;70:e30608.
Ruderfer D, Wu M, Wang T, Srivaths PR, Krance RA, Naik S, et al. BK virus epidemiology, risk factors, and clinical outcomes: an analysis of hematopoietic stem cell transplant patients at Texas Children’s Hospital. J Pediatr Infect Dis Soc. 2021;10:492–501.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42:1766–75.
Kwon MC, Thuring JW, Querolle O, Dai X, Verhulst T, Pande V, et al. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood 2024;144:1206–20.
Devillier R, Peffault De Latour R, Chevallier P, Huynh A, Chiusolo P, Bauquet A, et al. SMART101 donor T-lymphoid progenitors to accelerate immune reconstitution post-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide: SI101-02 first-in-human phase I/II. Blood 2023;142:4861.
Duléry R, Malard F, Brissot E, Banet A, Sestili S, Belhocine R, et al. Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation. Bone Marrow Transplant. 2023;58:1215–22.
Acknowledgements
We would like to thank the Francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC), to all the Swiss, Belgian and French centers that participated and completed the missing data. We would also like to thank Nicole Raus for her help in extracting data from the PromiSe database. Clinical number registry: Health DataHub registry number F20230327154245.
Author information
Authors and Affiliations
Contributions
CC and JHD designed the research study. CC and CH performed the research, analyzed the data and wrote the paper. LV analyzed the data and revised manuscript. FC, CN, BB, MA, AS, AG, MA, VG, PS, CHD, PSR, CP, CP, SNG, NR, MS, FM, ND and JHD revised the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and patient consent
Patients or legal guardians provided written informed consent for data collection and use for analysis, in accordance with the Declaration of Helsinki. This study was approved by SFGM-TC and SFCE HSCT committees and registered on Health Data Hub (F20230327154245).
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Calvo, C., Hautefeuille, C., Vasseur, L. et al. Real-world outcomes of haplo-HSCT with post-transplant cyclophosphamide in pediatric hematologic malignancies: a study on behalf of SFGM-TC and SFCE. Bone Marrow Transplant 60, 917–920 (2025). https://doi.org/10.1038/s41409-025-02584-4
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41409-025-02584-4
